176 related articles for article (PubMed ID: 18524847)
61. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
62. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
63. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
64. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
[TBL] [Abstract][Full Text] [Related]
65. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
[TBL] [Abstract][Full Text] [Related]
66. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
[TBL] [Abstract][Full Text] [Related]
67. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
68. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
69. [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].
Zhu XL; Cai X; Zhang L; Yang F; Sheng WQ; Lu YM; Du X; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):584-9. PubMed ID: 23157824
[TBL] [Abstract][Full Text] [Related]
70. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
[TBL] [Abstract][Full Text] [Related]
71. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.
Rebersek M; Mesti T; Boc M; Ocvirk J
Radiol Oncol; 2019 Mar; 53(1):85-95. PubMed ID: 30840593
[TBL] [Abstract][Full Text] [Related]
72. Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas.
Hirata AS; Rezende-Teixeira P; Machado-Neto JA; Jimenez PC; Clair JJ; Fenical W; Costa-Lotufo LV
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885944
[TBL] [Abstract][Full Text] [Related]
73. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.
Greshock J; Nathanson K; Medina A; Ward MR; Herlyn M; Weber BL; Zaks TZ
Genes Chromosomes Cancer; 2009 May; 48(5):419-28. PubMed ID: 19226609
[TBL] [Abstract][Full Text] [Related]
74. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
75. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
76. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
[TBL] [Abstract][Full Text] [Related]
77. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
78. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
79. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
[TBL] [Abstract][Full Text] [Related]
80. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
